WE CLAIM:

1. A pharmaceutical composition comprising a solid dispersion of a pharmaceutical compound, a water soluble carrier, and a crystallization inhibitor selected from the group consisting of polyvinylpyrrolidone (PVP) and hydroxypropylcellulose (HPMC).

2. The composition of Claim 1 wherein said water soluble carrier is polyethylene glycol (PEG).

3. The composition of Claim 1 wherein said pharmaceutical compound is an HIV protease inhibitor dissolved in an organic solvent.

4. The composition of Claim 3 wherein said organic solvent is ethanol.

5. The composition of Claim 3 wherein said HIV protease inhibitor is 2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-amino-1,6-diphenyl-3-hydroxyhexane (ritonavir).

6. The composition of Claim 3 wherein said HIV protease inhibitor is (2S, 3S, 5S)-2-(2,6-Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyl-butanoyl] amino-1,6-diphenylhexane (ABT-378).

7. The composition of Claim 3 wherein said HIV protease inhibitor is a combination of 2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-amino-1,6-diphenyl-3-hydroxyhexane (ritonavir) and (2S, 3S, 5S)-2-(2,6-Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl] amino-1,6-diphenylhexane (ABT-378).

8. The composition of Claim 2 wherein said solid dispersion is encapsulated in a hard gelatin capsule.

9. The composition of Claim 2 wherein said solid dispersion is compressed into a tablet.

10. The composition of Claim 1 further comprising an additive or a mixture of additives independently selected

from the group consisting of pharmaceutically acceptable surfactants and antioxidants.

11. The composition of Claim 1 wherein said pharmaceutical compound is fenofibrate.

12. The composition of Claim 1 wherein said pharmaceutical compound is griseofulvin.

13. A method of preparing a composition of Claim 1 which comprises:

a) dissolving a pharmaceutical compound inhibitor into an organic solvent to form a solution;

b) adding a water soluble carrier to said solution to form a mixture;

c) adding PVP to said mixture of step b);

d) optionally flash evaporating said solvent;

e) optionally drying the resulting residue remaining after evaporation;

f) optionally grinding and sieving the solid dispersion to obtain a resultant product.

14. The method of Claim 13 additionally comprising encapsulating the solid dispersion in a hard gelatin capsule.

15. The method of Claim 13 additionally comprising compressing said solid dispersion into a tablet.

16. The method of Claim 13 wherein said pharmaceutical compound is an HIV protease inhibitor.

17. The method of Claim 16 wherein said HIV protease inhibitor is selected from the group consisting of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-amino-1,6-diphenyl-3-hydroxyhexane (ritonavir) and (2S, 3S, 5S)-2-(2,6)-Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl] amino-1,6-diphenylhexane (ABT-378).

18. The method of Claim 13 wherein said solvent is ethanol.

19. The method of Claim 13 wherein said water soluble carrier is polyethylene glycol (PEG).

20. A method of treating an HIV infection comprising administering an effective amount of a solid dispersion of Claim 1 to a mammal in need of such treatment, wherein said pharmaceutical compound is an HIV protease inhibitor.

21. The method of Claim 20 wherein said HIV protease inhibitor is selected from the group consisting of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-amino-1,6-diphenyl-3-hydroxyhexane (ritonavir) and (2S, 3S, 5S)-2-(2,6)-Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl] amino-1,6-diphenylhexane (ABT-378).

22. A method of treating hyperlipidemia comprising administering an effective amount of a solid dispersion of Claim 1 to a mammal in need of such treatment, wherein said pharmaceutical compound is fenofibrate.

23. A method of treating a fungal infection comprising administering an effective amount of a solid dispersion of Claim 1 to a mammal in need of such treatment, wherein said pharmaceutical compound is griseofulvin.